Employers who win in this space: Lead with behavior change Set medication boundaries Require outcome tracking Build a clinical off-ramp With the right design, covering GLP-1s becomes more than a benefit it becomes a business case for long-term health, productivity, and cost control
Graphical Abstract Keywords Metabolic dysfunction-associated steatotic liver disease, Glucagon-like peptide-1 receptor agonist, Clinical trial, Treatment, Metabolic dysfunction-associated steatohepatitis, Fibrosis Introduction Nonalcoholic fatty liver disease has been used to describe hepatic steatosis without significant alcohol intake
If you are fortunate enough to qualify for insurance, you might be able to pay as little as $25 for a months prescription
Soldin, O
Roullet FI, Lai JKY, Foster JA (2013) In utero exposure to valproic acid and autism A current review of clinical and animal studies
Why is individualized care important in weight loss management